Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged ...
Recordati Rare Diseases Inc. today announced the presentation of real-world data that build upon the safety data of sutimlimab, an FDA-approved therapy for hemolysis in adults with cold agglutinin ...
In 2023, Japan's market size for Paroxysmal Nocturnal Hemoglobinuria therapeutics was around USD 88.5 million, with expectations of growth throughout the forecast period (2024-2034). Projections ...
Three recently published studies by Medical University of South Carolina researchers each adopted a unique approach to ...
Novel oral GRK2-biased β2 adrenergic receptor agonists show potential for safer glucose management and obesity treatment.
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
A new comprehensive analysis indicates that nitrous oxide, commonly known as laughing gas, provides rapid relief for adults suffering from severe forms of depression. The findings suggest that this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback